肝癌前病变的早期防治对于降低肝癌的发病率及死亡率具有重要的临床意义。基于鳖甲煎丸抗肝纤维化、肝硬化及肝癌研究的良好工作基础，以及肝卵圆细胞上皮间质转化与肝癌前病变密切相关的研究进展，本研究拟以肝卵圆细胞上皮间质转化为切入点，以大鼠肝卵圆细胞模型、大鼠肝癌前病变动态动物模型及临床肝癌患者术后肝脏病理组织标本为研究对象，采用质粒转染、基因沉默、免疫荧光检查及PCR等技术，探讨PI3K/AKT/GSK-3β信号通路调控肝卵圆细胞上皮间质转化向肝癌细胞恶性增殖转化的癌变机制。同时，应用活体小动物瘤体成像动态观察和免疫组织化学法等技术，研究鳖甲煎丸是否通过干预肝卵圆细胞上皮间质转化而达到抗肝癌前病变的分子机制。本研究对筛选肝癌前病变的诊断、治疗及预后的有效指标和寻找新的治疗靶点具有重要的临床价值，亦有助于进一步诠释鳖甲煎丸多途径、多层次抗肝癌前病变的科学内涵。

Early prevention and treatment of liver precancerous lesion are of significant importance for reducing incidence and mortality of liver cancer in clinical practice. Based on the good foundation of studies on Biejiajian Pills’s anti-liver fibrosis,anti-liver cirrhoisis and anti-liver cancer functions and research advancement of the close relationship between hepatic oval cell (HOC)'s epithelial-mesenchymal transition (EMT) and liver precancerous lesion, this study will take HOC’s EMT as the entry point to explore the tumorigenic mechanism of HOC’ EMT converting into malignant proliferation of liver cancer cells regulated by PI3K/AKT/GSK-3β signaling pathway. The research objects will include rat HOC models, dynamic models of rat liver precancerous lesion,and postoperative liver pathologic tissues of liver cancer patients. Methods such as plasmid tranfection, gene silencing, immunofluorescence and polymerase chain reaction will be applied in our study. To probe further into molecular mechanism of Biejiajian Pills inhibiting liver precancerous lesion whether by interfering in HOC’s EMT, small animal in vivo imaging system and immunohistochemistry will also be adopted. This study will be of great value in screening the efficacious index of diagnosis, treatment and prognosis of liver precancerous lesion and identifying novel therapeutic targets of liver cancers. What’s more, it will also contribute to elucidating the scientific essence of Biejiajian Pills’ multi-way and multi-level anti liver fibrosis function.